Health Care · Biological Products, (No Diagnostic Substances)

DNLI Denali Therapeutics Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 171489985 filings
Russell 2000

DNLI at a glance

Denali Therapeutics Inc. (DNLI, SEC CIK 1714899) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Denali Therapeutics Inc. (DNLI) reported revenue of $0 and a net loss of $512.5 million. Diluted EPS was -$2.97.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Denali Therapeutics Inc. (DNLI) shares worth $1.1 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Chin Peter Scott on September 4, 2026 of 1,654 shares at $22.29 per share.
  • In the last 90 days, DNLI insiders reported 0 open-market purchases ($0) and 4 open-market sales ($364K) on Form 4, a net sale of $364K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
0 buys · 4 sells
Net −$364K
13F holders
30 funds
$1.1B · +1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • FDA regulatory risk: Phase 2/3 HEALEY ALS trial of DNL343 missed primary endpoints in Jan 2025, risking program discontinuation or delays
  • Geopolitical/macro exposure: $966.2M cash runway through 12+ months threatened by inflation, tariffs, foreign currency risks, and economic downturns
  • Supply chain: Reliance on third parties for clinical trial manufacturing and raw materials may cause shortages or delays in product supply
  • Competition: Risk from other neurodegenerative disease biotech firms as limited approved therapies increase pressure to demonstrate efficacy first
  • Financial risk: Accumulated deficit $2.05B with $512.5M net loss in 2025; no product revenue, ongoing need for additional financing to continue development

Management Discussion & Analysis

  • Revenue recognition requires significant judgment on collaboration arrangements; no material revenue true ups reported to date
  • Research & development (R&D) expenses mainly external, based on estimates from progress reports; no material true ups in R&D expenses or reimbursements to date
  • Increasing judgment required for R&D expense estimates due to more extensive late-stage clinical trials
  • R&D funding payments recorded as liability and offset to R&D expenses; no material true ups in funding recognition

Business Overview

  • Core business: Developing biotherapeutics using proprietary TransportVehicle™ (TV) technology to cross blood-brain barrier and treat neurodegenerative and lysosomal storage diseases
  • New emphasis: Advancing two near-launch products (tividenofusp alfa for MPS II (Hunter syndrome) and DNL126 for MPS IIIA) with $1B+ initial market opportunity
  • Strategic shift: Transitioning from platform validation to commercial delivery with D3X3 strategy targeting two commercial brands, five clinical proof-of-concept readouts, and 4-6 new clinical programs (2026-2028)
  • Quantitative highlight: Over 200 clinical trial participants dosed with 11,000+ TV-enabled therapeutic doses; commercial readiness established including dedicated commercial team
  • Noteworthy fact: April 5, 2026 PDUFA date for tividenofusp alfa’s FDA accelerated approval BLA with expected first product launch, despite regulatory review extension due to major amendment

AI summary of the DNLI 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors previously disclosed in the 2025 Form 10-K and 2026 quarterly filings

Management Discussion & Analysis

  • Quarterly revenue $17.8M, versus $0 prior year, from AVLAYAH commercialization
  • Operating loss $126.8M, operating margin -713.1% versus not meaningful prior year
  • Net income $70.1M versus $126.9M loss, including $194.0M priority review voucher gain
  • Cash, equivalents and marketable securities $1.0B; operating cash use $345.6M year-to-date
  • AVLAYAH revenue not expected to offset expenses near term; zafinofusp BLA submission remains on track for 2027

AI summary of the DNLI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Full financial results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 net product revenue $17.8M, AVLAYAH’s second full commercial quarter, with Q4 guidance of $30.0M-$32.0M
  • U.S. commercial coverage exceeded 70%, up from more than 50%, with 20 state Medicaid programs covering AVLAYAH
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026
  • Press release contains Denali’s detailed financial results and operating updates

Item EX-99.1: Item EX-99.1

  • AVLAYAH launch generated $3.6M Q2 net product revenue; projected Q3 revenue of $10.0M-$12.0M signals rapid commercial ramp
  • Coverage expanded to more than 50% of covered lives and 14 Medicaid programs, supporting near-term prescription growth
Filed Jul 28, 2026Full analysis →

Item 2.01: Completion of Acquisition or Disposition of Assets

  • Denali completed sale of its Rare Pediatric Disease PRV on July 27, 2026
  • $195.0 million gross proceeds received at closing, providing substantial non-dilutive liquidity

AI summaries of DNLI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DNLI

Don't miss the next DNLI filing

  • Alerts as it files. A push when DNLI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DNLI, by share count.
  • Ask anything. An AI agent that reads every DNLI filing and answers with sources.

DNLI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Schuth Alexander O.MNov 17, 2026$9.60
Schuth Alexander O.MNov 17, 2026-
Chin Peter ScottSellSep 4, 2026$22.29
Thornberry NancySellSep 2, 2026$22.85
Thornberry NancySellSep 2, 2026$23.74
Schuth Alexander O.SellSep 1, 2026$23.44
Watts Ryan J.GAug 12, 2026-
Schuth Alexander O.SellAug 11, 2026$25.07

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$0
Operating Income--$487.3M-$555.3M
Net Income-$145.2M-$422.8M-$512.5M
Balance Sheet
Total Assets-$1.4B$1.1B
Equity$1.0B$1.2B$1.0B
ROE-14.1%-34.4%-50.6%
Per Share
EPS$-1.06$-2.57$-2.97
Cash Flow
Operating CF--$347.7M-$412.6M
CapEx$12.9M$15.9M$9.5M

Source: XBRL data in Denali Therapeutics Inc. (DNLI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DNLI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DNLI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$1.13B
Q2 202629$1.49B
Q1 202628$1.04B
Q4 202526$936.8M
Q3 202528$794.5M
Q2 202528$773.8M
Q1 202524$491.9M
Q4 202419$651.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 212 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DNLI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
8-KNov 3, 2026Analysis-
10-QNov 3, 2026Analysis
4Sep 9, 2026--
4Sep 4, 2026--
4Sep 3, 2026--
4Aug 14, 2026--
4Aug 13, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
8-KJul 28, 2026Analysis-
8-KJun 18, 2026Analysis-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
8-KJun 4, 2026Analysis
8-KMay 22, 2026Analysis
SC 13GMay 15, 2026-
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis

Related Health Care companies

All Health Care →

DNLI SEC filings: frequently asked questions

Are DNLI insiders buying or selling?

In the last 90 days, Denali Therapeutics Inc. (DNLI) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $363,678 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold DNLI stock?

As of September 30, 2026, the largest Denali Therapeutics Inc. (DNLI) holders among the 13F filers tracked by SignalX were BlackRock ($296.2 million), Vanguard Portfolio Management LLC ($139.7 million), Vanguard Capital Management LLC ($139.5 million), State Street Corp ($138.1 million), Goldman Sachs Group ($77.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was DNLI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Denali Therapeutics Inc. (DNLI) reported revenue of $0 and a net loss of $512.5 million. Diluted EPS was -$2.97. The figures come from the XBRL data in the 10-K.

What are the main risks in DNLI's latest 10-K?

In the 10-K filed February 26, 2026, Denali Therapeutics Inc. (DNLI) flagged: FDA regulatory risk: Phase 2/3 HEALEY ALS trial of DNL343 missed primary endpoints in Jan 2025, risking program discontinuation or delays. Geopolitical/macro exposure: $966.2M cash runway through 12+ months threatened by inflation, tariffs, foreign currency risks, and economic downturns. (AI summary of the Risk Factors section.)

What did DNLI report in its latest 8-K?

Denali Therapeutics Inc. (DNLI) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.

What are the latest DNLI SEC filings?

Denali Therapeutics Inc. (DNLI) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 19, 2026.

What is DNLI's SEC CIK number?

Denali Therapeutics Inc. (DNLI)'s SEC Central Index Key (CIK) is 1714899. EDGAR lists every DNLI filing under that number.

Ask anything about DNLI

The research agent reads DNLI's filings, financials, insider trades and 13F holders, then answers with sources.